Healthcare / Health Information ServicesNYSE
$26.99
+1.87 (+7.44%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-10.5M · quality 45.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
37/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$460M
P/E
N/A
•EV/EBITDA
10.8x
↓ROE
163.5%
↑Gross Margin
67.2%
↑Debt/Equity
-26.54
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2018–2025 · 7 años de histórico normalizado
Revenue CAGR
-1.1%
FCF CAGR
—
FCF margin
-1.3%
FCF / Net income
0.04x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $965.4M · net income $-284.3M · FCF $-12.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | $965.4M | $965.4M | $930.6M | $961.5M | $1.08B | $1.12B | $937.8M | $982.9M | $1.04B |
| Net Income | $-284.3M | $-284.3M | $-1.65B | $-91.7M | $-572.9M | $102.1M | $-520.6M | $9.7M | $36.2M |
| EBITDA | $467.4M | $467.4M | $-1.01B | $651.9M | $158.3M | — | — | — | — |
| EPS | -17.30 | -17.30 | -101.92 | -5.69 | -36.00 | 6.40 | -44.40 | 0.80 | — |
| Gross Margin | 67.2% | 67.2% | 67.4% | 69.3% | 81.1% | — | — | — | — |
| Operating Margin | 4.7% | 4.7% | 11.6% | 17.8% | 31.0% | 34.5% | -14.1% | 37.5% | 41.1% |
| Net Margin | -29.4% | -29.4% | -176.9% | -9.5% | -53.1% | 9.1% | -55.5% | 1.0% | 3.5% |
| Balance Sheet | |||||||||
| Debt/Equity | -26.54 | -26.54 | 54.05 | 2.67 | 2.67 | 2.12 | — | — | — |
| Current Ratio | 1.28 | 1.28 | — | — | — | — | — | — | — |
| Cash Flow | |||||||||
| Free Cash Flow | $-12.3M | $-12.3M | $-10.5M | $62.9M | $282.6M | $320.1M | $306.6M | $217.9M | $228.7M |
| Returns | |||||||||
| ROE | 163.5% | 163.5% | -1958.8% | -5.4% | -32.0% | 4.4% | -20.4% | 0.5% | 1.8% |
| Valuation | |||||||||
| EV/EBITDA | 10.79 | 10.79 | — | 8.16 | 32.74 | — | — | — | — |
| P/B | — | — | 2.73 | 0.48 | 0.41 | — | — | — | — |
| Growth & Yield | |||||||||
| Revenue Growth | 3.7% | 3.7% | -3.2% | -10.9% | — | 19.2% | -4.6% | -5.6% | — |
| EPS Growth | 83.0% | 83.0% | -1691.2% | 84.2% | — | 114.4% | -5650.0% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-29.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-101.92 → -17.30
Residual
-29.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.